Enhancing cross-subject EEG emotion recognition through multi-source manifold metric transfer learning.

Transfer learning (TL) has demonstrated its efficacy in addressing the cross-subject domain adaptation challenges in affective brain-computer interfaces (aBCI). However, previous TL methods usually use a stationary distance, such as Euclidean distance, to quantify the distribution dissimilarity between two domains, overlooking the inherent links among similar samples, potentially leading to suboptimal feature mapping. In this study, we introduced a novel algorithm called multi-source manifold metric transfer learning (MSMMTL) to enhance the efficacy of conventional TL.

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China.

Introduction: A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection. We conducted a phase 3 study to evaluate the efficacy and safety of alfosbuvir in combination with daclatasvir in Chinese patients with HCV infection.

Cross-subject EEG emotion recognition using multi-source domain manifold feature selection.

Recent researches on emotion recognition suggests that domain adaptation, a form of transfer learning, has the capability to solve the cross-subject problem in Affective brain-computer interface (aBCI) field. However, traditional domain adaptation methods perform single to single domain transfer or simply merge different source domains into a larger domain to realize the transfer of knowledge, resulting in negative transfer. In this study, a multi-source transfer learning framework was proposed to promote the performance of multi-source electroencephalogram (EEG) emotion recognition.

Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.

Background: SH-1028 is a new third-generation EGFR tyrosine kinase inhibitors (TKI) to benefit patients with EGFR T790M-mutated NSCLC. Here, the authors report its clinical safety, preliminary efficacy, and pharmacokinetic (PK) profile for the first time.

Methods: Patients with EGFR T790M mutation, locally advanced non-small cell lung cancer (NSCLC), or metastatic NSCLC who had progressed after previous EGFR TKI therapy were eligible.

The lncRNA PVT1/miR-423-5p axis is positively correlated with the severity of bronchial asthma.

Bronchial asthma (BA) is a serious problem affecting the quality of life of patients. Long noncoding RNAs (lncRNAs) are involved in BA. This study set out to investigate expressions of PVT1/miR-423-5p in the serum of BA patients and its clinical value on BA diagnosis and evaluation.